Gene Manipulation

Cellular Therapies: Transforming Treatment for Thalassemia and Sickle Cell Disease

Thalassemia and sickle cell disease are two of the most prevalent blood disorders, affecting millions worldwide. These genetic conditions often result in severe complications, including anemia, organ damage, and reduced quality of life. While traditional treatments like blood transfusions and iron chelation offer temporary relief, they fall short of providing a long-term solution.

We are pioneering advanced cellular therapies to revolutionize the treatment landscape for these disorders. Through gene-editing techniques such as CRISPR and stem cell transplantation, cellular therapies target the root cause of the disease. By reprogramming or replacing faulty hematopoietic stem cells, these therapies enable the body to produce healthy, functional red blood cells, offering a potential cure rather than mere symptom management.

These cutting-edge solutions not only improve patient outcomes but also reduce the long-term healthcare burden associated with chronic treatments. Our mission is to make these life-changing therapies accessible and affordable, especially in regions where these conditions are most prevalent.

At the heart of our innovation is the promise of a better future for patients and families affected by thalassemia and sickle cell disease—transforming lives with every breakthrough.

1980

Discovery of Genetic Basis of Blood Disorders

Identification of mutations in the HBB gene as the cause of sickle cell anemia and thalassemia.

1990

Early Gene Therapy Attempts

First attempts at gene therapy using viral vectors to introduce functional copies of the HBB gene.
Challenges included immune responses and low efficiency of gene integration.

2002

Development of RNA Interference (RNAi)

RNAi used to silence genes involved in the disease process, an early tool for understanding gene function and disease mechanisms.

2012

CRISPR-Cas9 Breakthrough

Discovery of CRISPR-Cas9 as a precise and efficient tool for gene editing revolutionizes genetic research.
Researchers start exploring its potential to correct mutations in the HBB gene.

2017

First CRISPR Gene-Edited Human Trials

Clinical trials begin for sickle cell anemia and beta-thalassemia using CRISPR to either correct mutations or activate fetal hemoglobin (BCL11A gene editing).

2019

Success in Thalassemia Treatment Using Gene Therapy

Patients with severe beta-thalassemia show reduced dependence on blood transfusions after undergoing gene therapy using lentiviral vectors.

2020

First CRISPR Cure for Sickle Cell Anemia Reported

A patient with sickle cell anemia is treated using CRISPR-based therapy, leading to significant reduction in disease symptoms.
Clinical trials continue, expanding to more patients worldwide.

2021

FDA Grants Breakthrough Status to CRISPR-Based Therapies

Gene editing treatments for sickle cell anemia and thalassemia receive special designation for accelerated approval.

2023

Approval of Exa-cel (CRISPR Therapeutic)

Exa-cel (exagamglogene autotemcel), a CRISPR-based therapy, is approved for treating sickle cell disease and beta-thalassemia in multiple countries.
First commercially available gene-editing therapy for these conditions.

2024

Widespread Clinical Application

Gene therapies are now available in several regions, showing high success rates in curing or significantly reducing symptoms of blood disorders.
Research continues to improve accessibility, scalability, and affordability.

----

Next 5-10 Years:

Potential for widespread adoption of gene therapies globally.
Expansion to treat other genetic blood disorders like Fanconi anemia and severe aplastic anemia.